Robert T. Fremeau, PhD

Dr. Robert T. Fremeau, Jr. is a molecular neuroscientist, pharmacologist, and biotech entrepreneur with over 20 years of experience advancing CNS discovery programs into clinical development across academia and industry. He has led target validation and small-molecule drug discovery efforts across neurodegenerative, neurodevelopmental, neuropsychiatric, and pain indications. Dr. Fremeau is the Founder and CEO of BrainStorm Therapeutics, where he is building an AI-powered CNS drug discovery platform that integrates patient-derived human brain organoids with computational and network biology approaches to generate predictive, human-relevant data. The platform is designed to improve translational success, enable earlier identification of disease-modifying therapies, and support precision patient stratification. Previously, he served as Chief Scientific Officer at Vyant Bio, where he built a platform-driven pipeline and advanced a Rett syndrome program into Phase 2 clinical development. Earlier, at Amgen, he served as Scientific Director in Neuroscience, leading cross-functional discovery teams and contributing to the advancement of 12 programs into clinical trials. Dr. Fremeau has authored over 65 publications (H-index 46), holds multiple patents, and trained at UCDF, Columbia University, and George Washington University.